Skip to content
10-Q

Quarterly Report

Apogee Therapeutics, Inc. APGE

0001193125-26-215698

← back to feed
Filed
May 11, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted Q1 2026 · Mar 31, 2026 69.67M sh
Shares Diluted Q1 2026 · Mar 31, 2025 58.2M sh
Shares Outstanding Q1 2026 · Mar 31, 2026 74.88M sh
Shares Outstanding Q1 2026 · Dec 31, 2025 68.4M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$55.57M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$48.48M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $451.8M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $106.92M
Current Liabilities Q1 2026 · Mar 31, 2026 $32.95M
Current Liabilities Q1 2026 · Dec 31, 2025 $27.91M
Total Liabilities Q1 2026 · Mar 31, 2026 $37.86M
Total Liabilities Q1 2026 · Dec 31, 2025 $33.25M
Current Assets Q1 2026 · Mar 31, 2026 $1.07B
Current Assets Q1 2026 · Dec 31, 2025 $741.36M
Total Assets Q1 2026 · Mar 31, 2026 $1.29B
Total Assets Q1 2026 · Dec 31, 2025 $937.13M
Eps Diluted Q1 2026 · Mar 31, 2026 −$1.06
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.95
Eps Basic Q1 2026 · Mar 31, 2026 −$1.06
Eps Basic Q1 2026 · Mar 31, 2025 −$0.95
Sga Expense Q1 2026 · Mar 31, 2026 $21.95M
Sga Expense Q1 2026 · Mar 31, 2025 $16.71M
Rd Expense Q1 2026 · Mar 31, 2026 $60.82M
Rd Expense Q1 2026 · Mar 31, 2025 $46.39M
Net Income Q1 2026 · Mar 31, 2026 −$74.11M
Net Income Q1 2026 · Mar 31, 2025 −$55.34M
Operating Income Q1 2026 · Mar 31, 2026 −$82.77M
Operating Income Q1 2026 · Mar 31, 2025 −$63.1M
Capex Q1 2026 · Mar 31, 2025 $4.32M